Kommentar
In glucocorticoid-dependent polymyalgia rheumatica, tocilizumab improved a composite clinical outcome at 24 wk
Annals of Internal Medicine · 2023
DOI: 10.7326/j22-0107 ↗Kurz gefasst
Kommentar in der Zeitschrift Annals of Internal Medicine, 2023. Verfasst von David S Pisetsky. Beteiligte Einrichtung: University Medical Center, Durham, North Carolina, USA (D.S.P.). Hauptthemen laut MEDLINE: Giant Cell Arteritis, Polymyalgia Rheumatica. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Giant Cell ArteritisPolymyalgia RheumaticaHumansAntibodies, Monoclonal, HumanizedGlucocorticoidsRandomized Controlled Trials as Topic
Substanzen
Antibodies, Monoclonal, HumanizedGlucocorticoidstocilizumab
Autor:innen und Institutionen
- University Medical Center, Durham, North Carolina, USA (D.S.P.).
Zitieren
APA
Pisetsky, D. S. (2023). In glucocorticoid-dependent polymyalgia rheumatica, tocilizumab improved a composite clinical outcome at 24 wk. Annals of Internal Medicine. https://doi.org/10.7326/j22-0107
Vancouver
Pisetsky DS. In glucocorticoid-dependent polymyalgia rheumatica, tocilizumab improved a composite clinical outcome at 24 wk. Annals of Internal Medicine. 2023. doi:10.7326/j22-0107
BibTeX
@article{Pisetsky2023,
author = {Pisetsky, David S},
title = {In glucocorticoid-dependent polymyalgia rheumatica, tocilizumab improved a composite clinical outcome at 24 wk},
journal = {Annals of Internal Medicine},
year = {2023},
doi = {10.7326/j22-0107}
}
EUVIMED